June 2008 Issue of MMM
Pharmaceutical marketers spend a lot of time and effort figuring out what makes physicians tick.
Reversing pharma's ragged reputation is no easy task. But good intentions abound. Ben Comer reports on AstraZeneca's attempts to put transparency at the center of ...
Novo Nordisk associate director, Craig DeLarge, shares his insights on the various ways pharma can leverage and integrate the increasingly popular virtual world of Second ...
With pharmaceutical companies cutting advertising costs across all channels—consumer and professional alike—media planners and buyers are looking for ways to do more with less and ...
Generating pre-launch marketing awareness is turbo-charging pharma product market share gains. Harte-Hanks SVP, pharmaceutical markets, Julian Parreño discusses how 'hypermarketing' has helped Teva Neuroscience drive ...
After nearly a quarter of a century in leadership communications roles at Bristol-Myers Squibb and Novartis, Robert Laverty signed on in April as VP, US ...
We are witnessing the death of pharma marketing research and the birth of healthcare marketing research.
I promise you that heparin is a perfectly good drug, though if you have been reading the newspapers lately, you wouldn't think so.
"Collaboration" was the buzzword at this year's Med Ed Congress, held May 7-9 in Philadelphia, but the uncertainty surrounding continuing education was certainly top of ...
Med Ed Report
Medical schools and teaching hospitals should ban gifts to physicians and other faculty, staff, students and trainees, whether on-site or off-site, including food and travel, ...
In its March meeting, the ACCME revisited the question of what constitutes a "commercial interest" ineligible for accreditation.
HMP Communications Holdings LLC has bought med ed firm Princeton Media Associates LLC.
Three former Sudler & Hennessey med ed companies have merged into one independent unit, dubbed IME, LLC, under the leadership of managing director Lisa Emusov.
MEBN, a New Hampshire medical education and communications company, has been awarded a four-year continuation of its accreditation status by ACCME.
The Accreditation Council for Continuing Medical Education (ACCME) is expanding its offices, moving into a new 3,000-square-foot space to accommodate 10 additional staff members.
From 2002 to 2006, average reported professional attendance at international medical meetings increased 23%, according to a report by the Healthcare Convention and Exhibitors Association.
Advanstar Communications announced plans to launch a Healthcare Centralized Content Group, and has partnered with Getty Images for digital imaging services.
The Journal of the American Medical Association called into question published clinical data and authorship surrounding Merck's Vioxx (rofecoxib) in a scathing editorial.
PeerView has completed the acquisition of the Veritas Clinical Trials Register platform from Veritas Medicine.
The American Heart Association has launched Circulation: Arrhythmia and Electrophysiology, an extension of its flagship journal.
Quadrant Healthcom Inc. (QHI) has named Eileen Hubert group publisher for Neurology Reviews and NeuroPsychiatry Reviews.
As the majority of the top pharmaceutical companies find themselves downsizing their sales forces, how will those professional marketing dollars be reallocated?
The Direct Marketing Association (DMA) released a study indicating significant growth and efficacy in the direct marketing industry through 2012.
Direct marketing agency Targetbase has launched XACT Direct-to-Patient, a proprietary modular suite delivering customer relationship management by way of marketing solutions for the healthcare industry.
The Aptilon Corporation released two new studies demonstrating that live online video detail sessions with physicians significantly impact prescribing behavior.
Harte-Hanks has announced plans to close a New Jersey office, one of its 30 company locations nationwide.
Merck announced plans to cut 1,200 sales jobs in the US.
Praxis, a company specializing in centralized patient recruitment for clinical research studies, appointed Chris Layfield as director of marketing.
Merck's Gardasil team cleaned up at last month's Phame Awards, winning honors for Best Branded TV, Best Branded Print and Best Integrated Campaign on the ...
Drug industry spend on consumer advertising dropped 3% in 2007 to $5.15 billion, from $5.31 billion in 2006, but spending on product advertising, particularly TV ...
The FDA issued a warning letter to Pfizer for not mentioning the risks of impotence pill Viagra in a video ad on CNN.com.
VeriChip Corp., which makes radio frequency identification devices for healthcare and patient-related needs, launched its first DTC campaign in South Florida at the end of ...
Cephalon reported that selling, general and administrative expenses jumped 30% in the first quarter to $199 million on DTC for narcolepsy drug Provigil (modafinil) and ...
The American College of Medical Genetics issued guidelines on genetic testing aimed at consumers amidst rising DTC advertising of the services.
The long tail of the Internet has been mentioned a few times in this column over the past few years. The long tail actually refers ...
WebMD parent company WebMD Health Corp has revised its outlook due to a lack of healthcare advertisers spending money with the firm.
Pfizer's smoking cessation treatment Chantix was the top-searched prescription brand online in February, generating more than 500,000 search queries, according to internet measurement firm comScor
The question of public relations versus other marketing spends is probably a debate that never will go quietly into the night.
Burson-Marsteller has appointed Gail Cohen to global chair of the firm's healthcare practice.
Websites aren't the only thing to consider when employing search engine optimization (SEO), according to PR practitioners and service providers.
Getting your brand noticed early in its lifespan is crucial to pharma product position strategy said, Corinne Le Goff, VP, marketing, at Sanofi-Aventis.
The market for obesity treatments will grow five-fold by 2016, according to research firm Decision Resources.
The worst idea on Capitol Hill right now involves giving the FDA control of tobacco.
Three key leaders of the House Energy and Commerce Committee are circulating a discussion draft of their proposed Food and Drug Administration Globalization Act of ...
FDA commissioner Andrew von Eschenbach was directed to "stop the buzzwords and toe-dancing" during intense, aggressive questioning by House Energy and Commerce chairman John D. ...
The FDA has a stale and outdated regulatory system for overseeing clinical trial compliance, but several initiatives are under way to modernize it, according to ...
An FDA plan to allow drug companies to distribute reprints of journal articles dealing with off-label drug uses has run into fire from Sen. Charles ...
Commissioner von Eschenbach told an April Senate hearing his agency could easily absorb an extra $100 million for FY 2009 to beef up medical product ...
FDA's latest annual report says 71% (911) of pending postmarketing study commitments promised by drug sponsors at the time of approval have never been started.
FDA identified 20 Rx drugs and biologics that must have an approved risk evaluation and mitigation strategy, including GlaxoSmith-Kline's Lotronex, Novartis' Clozaril, Cephalon's Actiq, Hoffmann-LaRoche's ...
FDA's Office of Generic Drugs ran out of appropriated funds April 3 and a hiring freeze was imposed.
One of the most useful skills I learned in high school was how to write book reports without reading the whole book.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.